Biogen looks to expand neuro pipeline via C4, Skyhawk deals

A pair of deals announced Friday leaves Biogen Inc. (NASDAQ:BIIB) poised to expand the druggable space of its neurology pipeline. Biogen entered R&D partnerships with targeted protein degradation company C4 Therapeutics Inc. (Cambridge, Mass.) and spliceosome company Skyhawk Therapeutics Inc. (Waltham, Mass.)

For more information visit:

www.skyhawktx.com

https://www.linkedin.com/company/skyhawk-therapeutics/

https://twitter.com/Skyhawk_Tx

SKYHAWK MEDIA CONTACT:

Maura McCarthy

maura@skyhawktx.com

Full Article